Design, Synthesis and Biological Testing of Cyclohexenone Derivatives of Combretastatin-A4
ACS Citation
Ruprich, J.; Prout, A.; Dickson, J.; Younglove, B.; Nolan, L.; Baxi, K.; LeBlanc, R.; Forrest, L.; Hills, P.; Holt, H. L., Jr.; Mackay, H.; Brown, T.; Mooberry, S. L.; Lee, M. Design, Synthesis and Biological Testing of Cyclohexenone Derivatives of Combretastatin-A4. Lett. Drug Des. Discovery 2007, 4, 144-148.
Version of Record
Abstract
Sixteen 2-cyclohexenone and 6-(ethoxycarbonyl)-2-cyclohexenone analogs of combretastatin-A4 (CA-4, 1) were synthesized, and their ability to inhibit the growth of two murine cancer cell lines (B16 melanoma and L1210 leukemia) was detd. using an MTT assay. One of the cyclohexenone analogs, 8, which contains the same substituents as CA-4 (1) is the most potent (IC50 = 0.91 μM, L1210). Exposure of A-10 aortic cells to cyclohexenone 8 (II)and its ester congener 7 (I)produced significant redn. in cellular microtubules, with EC50 values of 27 and 37 μM, resp. Mol. modeling studies indicate that analog 8 adopts a twisted conformation, similar to CA-4, suggesting that conformation and structure are crucial for activity. These compds. are worthy of further investigation as potential tubulin inhibitors in the quest for novel anti-cancer agents.
Source Name
Letters in Drug Design & Discovery
Publication Date
1-1-2007
Volume
4
Issue
2
Page(s)
3568-3575
Document Type
Citation
Citation Type
Article